Rates of John Cunningham virus seroconversion greatly reduced in natalizumab-treated patients during COVID-19-related lockdowns.

Christopher M DwyerSifat SharminTomas Kalincik

Published in: European journal of neurology (2023)

JCV seroconversion among natalizumab-treated patients was markedly lower during COVID-19-related community restrictions. Restrictions observed in Melbourne were among the longest and most comprehensive implemented worldwide. This suggests the presence of modifiable risk factors that could lower rates of JCV seroconversion among natalizumab-treated patients.

Keyphrases

end stage renal disease
newly diagnosed
multiple sclerosis
ejection fraction
chronic kidney disease
peritoneal dialysis
healthcare
prognostic factors
mental health